The article provides an overview of analyst ratings for Foghorn Therapeutics in the last quarter. With 3 bullish and 3 somewhat bullish ratings, the sentiment is generally positive. However, the average 12-month price target has decreased by 18.35% from the previous average, indicating a potential short-term neutral impact on the stock price.